Abstract: Worldwide morbidity and mortality of acute myocardial infarction(AMI)and related heart failure are still high. While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical and effective treatment at present, collateral myocardial ischemia reperfusion injury(MIRI)and pertinent cardioprotection are still challenging to address and have inadequately understood mechanisms. Therefore, unveiling the related novel molecular targets and networks participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier. The present study specifically focuses on the recent MIRI advances that are supported by sophisticated molecular pharmacology in order to bring the poorly understood interrelationship among MIRI participant molecules up to date, as well as to identify findings that may facilitate the new drug of novel targets.

Key words: myocardial ischemia, ischemia reperfusion injury, mitochondrial factors, immune molecular targets

CLC Number: